Clinical Advancements In Kura Oncology's Lead Program Ziftomenib Hint at Upsurge in Success Likelihood: Analyst
Portfolio Pulse from Vandana Singh
Mizuho initiated coverage on Kura Oncology Inc (NASDAQ:KURA), highlighting the potential of its lead program ziftomenib for treating r/r NPM1-m AML. The firm sees a higher likelihood of success as more data becomes available, which could double the market reach and positively impact KURA's valuation. Analysts Mara Goldstein and Jerry Gong issued a Buy rating with a $26 price target. KURA shares rose 9.73% to $13.79 after the coverage initiation.
December 22, 2023 | 5:50 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Mizuho initiated coverage on Kura Oncology with a positive outlook on ziftomenib, issuing a Buy rating and a $26 price target. The anticipation of clinical success for ziftomenib has already led to a 9.73% increase in KURA's stock price.
The initiation of coverage by Mizuho with a positive outlook and a high price target suggests strong confidence in Kura Oncology's lead program. This endorsement, along with the potential expansion of the market reach, is likely to generate investor interest and could lead to a short-term increase in stock price, as evidenced by the recent surge.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100